祖明远：绵阳是中国科技城，正通过产学研用协同创新，推动院所的先进技术转化为创新产品。以刚刚 提到的E-Flash产品为例，通过在极短时间内释放超高剂量率的电子射线对肿瘤进行治疗，可大幅提升 癌细胞杀伤效率，具有治疗时间短、正常组织损伤小、治疗成本低等优势。目前，已在四川大学华西医 院等开展临床试验。 张剑：有了"素"和"装备"，还需要解决"有人用"的问题，这正是泸州的长项。 四川在线记者 祖明远 张剑 林凌 摄影 韦维 剪辑 周芷冰 今年省政府工作报告提到"加快培育新兴产业未来产业"。作为未来的万亿产业，核医疗在四川大有可 为，是部分代表委员高度关心的话题。四川核医疗产业主要布局在乐山、成都、绵阳、泸州等地，怎样 建圈强链？今天，听完施小琳省长所作政府工作报告后，四川日报驻乐山、绵阳、泸州的三位记者碰了 个头，就这个"硬核"话题聊开来。 祖明远：在四川，一批创新核医疗诊疗方法正在涌现。例如，只需0.03秒就可以完成一次放疗的E-Flash 产品，在精准杀伤肿瘤的同时，能让人体损伤更小。这款四川创新的核医疗产品正在开展临床试验。 林凌：要让这样的创新诊疗方法走向现实，还需要4项要素，也正对应4个城市，分别是：乐 ...

Core Insights - The first China Particle Medical and Equipment Industry Development Conference was held in Chengdu, focusing on using particle technology for more precise and gentle cancer treatment [1] - Particle therapy, including proton and heavy ion therapy as well as emerging BNCT (Boron Neutron Capture Therapy), is a cutting-edge treatment method in the nuclear medical industry [1] - The particle medical industry is emerging as a trillion-yuan market, with Sichuan province, particularly Chengdu, playing a central role in developing a complete nuclear medical industry chain [1] Industry Development - Chengdu is attracting leading companies like Yuan Da Pharmaceutical and Newray, forming a collaborative industrial hub in Tianfu International Biocity, which focuses on targeted drugs, high-end equipment, and core software [2] - The future development of nuclear medicine in Chengdu will focus on three main directions: enhancing research and clinical translation of new targeted therapies and high-end diagnostic equipment, attracting corporate headquarters and R&D platforms, and providing one-stop services through policy support and platform construction [2]

Core Insights - The strategic cooperation seminar held by Guangzhou Pharmaceutical Group and Guangzhou Baiyunshan Pharmaceutical Group focused on the theme "New Journey Without Boundaries, Together Towards the Future" and gathered over 430 guests from various sectors [1][2] - Guangzhou Pharmaceutical Group aims to achieve modernization, digitalization, technological advancement, and internationalization as part of its "14th Five-Year Plan" to accelerate the goal of "recreating a new Guangzhou Pharmaceutical" [1] Group 1 - Guangzhou Pharmaceutical Group's capital operations are robust, with a fund subscription scale of 4.7 billion yuan and actual contributions of 2.4 billion yuan, focusing on innovative drugs and high-end medical devices [1] - The company is advancing its technological innovation with nearly 20 new drugs under research and 26 new product projects added this year [1] - International expansion is entering a new phase, with ongoing efforts to explore markets in Southeast Asia, the Middle East, and South America [1] Group 2 - A key highlight of the seminar was the announcement of the nuclear medicine industry layout and the innovative achievements of Guangzhou Baiyunshan's nuclear health pharmaceutical company [2] - A strategic cooperation agreement was signed between Baiyunshan and GE Healthcare to empower the high-quality development of the nuclear medicine industry through cross-industry collaboration [2] - The launch of the "China Innovative Drug R&D and Industry Development Research Report Project" aims to integrate resources across the industry chain and address challenges in innovative drug development, supporting China's transition from a major pharmaceutical country to a strong pharmaceutical nation [2]

Core Insights - The "World Fusion Energy Group" held its second ministerial meeting and the 30th International Conference on Fusion Energy in Chengdu, where Sichuan province announced 24 policy measures to promote the high-quality development of the nuclear medicine industry [1][12] - Chengdu is positioning itself as a leader in the nuclear medicine sector, focusing on the entire industry chain from the production of medical isotopes to the development of radiopharmaceuticals and manufacturing of nuclear medical equipment [3][6] Policy Measures - Sichuan's new policies aim to support precise targeting, industrial upgrades, expanding application demands, and creating a favorable development environment [1] - The release of an opportunity list in the nuclear medicine sector highlights Chengdu's commitment to developing three nuclear drug bases [1] Industry Developments - Chengdu's nuclear medicine sector has seen significant advancements, including the clinical approval of innovative nuclear drugs and substantial financing for nuclear medicine companies [3][4][12] - The establishment of the Fosun Pharma nuclear drug platform in Chengdu marks a strategic move to enhance research and development in the nuclear medicine field [9][10] Innovation and Breakthroughs - Chengdu's Baile Tianheng received approval for its first antibody-radiolabeled drug, which is expected to significantly improve treatment for advanced or metastatic solid tumors [4] - The successful development and export of a domestically produced germanium-gallium generator by Chengdu's Nureter Medical Technology represents a breakthrough in the self-sufficiency of medical isotopes [5] Ecosystem and Collaboration - Chengdu is fostering a collaborative ecosystem that integrates policy support, capital investment, talent attraction, and industry-academia cooperation to enhance the nuclear medicine industry [12][13] - The establishment of specialized parks and research centers in Chengdu is aimed at creating a comprehensive support system for nuclear medicine innovation [11][14]

Core Viewpoint - The Guangdong Provincial Development and Reform Commission has issued an action plan to accelerate the high-quality development of the nuclear medicine industry from 2025 to 2030, aiming for significant improvements in innovation capabilities, key technology breakthroughs, and the establishment of a competitive nuclear medicine industry cluster by 2030 [1][3]. Industry Development - The nuclear medicine industry is experiencing unprecedented growth opportunities due to global aging populations, rising chronic disease rates, and continuous technological innovations [2]. - Recent favorable policies at both national and local levels are propelling the rapid development of the nuclear medicine industry in China, with a focus on enhancing innovation capabilities and expanding application fields [3]. Market Size - According to a report by Zhongyan Puhua Industry Research Institute, the global nuclear medicine market is expected to exceed $100 billion by 2025, with a compound annual growth rate of over 10%, potentially reaching over $200 billion by 2030 [4]. Company Developments - Companies in the nuclear medicine sector are actively advancing their positions, with Shanghai United Imaging Healthcare Co., Ltd. recently obtaining a patent for a scanning method for nuclear medicine devices [5]. - Qingdao Baiyang Pharmaceutical Co., Ltd. announced that its radiopharmaceutical, a first-class new drug in China, has successfully met key clinical trial endpoints, addressing significant challenges in tumor imaging diagnostics [5]. Challenges - The nuclear medicine field faces challenges due to high technical barriers and strict regulatory policies, requiring substantial investment in research and development to overcome technological bottlenecks [6]. - Market awareness of nuclear medicine products is relatively low, and the high costs associated with these technologies pose additional challenges for widespread adoption [6].

Economic Performance - In May, the national economy showed stable growth with industrial production increasing by 5.8% year-on-year, and equipment manufacturing and high-tech manufacturing growing by 9% and 8.6% respectively, outpacing the overall industrial growth by 3.2 and 2.8 percentage points [1] - The service sector's production index rose by 6.2% year-on-year in May, with significant contributions from information transmission, software, and IT services (11.2%), leasing and business services (8.9%), and wholesale and retail (8.4%) [1] - Retail sales saw a notable recovery, with total retail sales of consumer goods reaching 41,326 billion yuan, a year-on-year increase of 6.4%, accelerating by 1.3 percentage points from the previous month [1] Employment and Prices - The urban survey unemployment rate in May was 5%, a decrease of 0.1 percentage points from the previous month, indicating overall employment stability [2] - The Consumer Price Index (CPI) fell by 0.1% year-on-year and 0.2% month-on-month, while the core CPI, excluding food and energy, increased by 0.6% year-on-year, reflecting a slight acceleration in inflation [2] Investment and Trade - Fixed asset investment (excluding rural households) from January to May totaled 191,947 billion yuan, growing by 3.7% year-on-year, with a notable 7.7% growth when excluding real estate development investment [1] - The total value of goods imports and exports in May reached 38,098 billion yuan, with exports increasing by 6.3% and imports decreasing by 2.1% [1] Corporate Developments - GAC Aion faced employee stock valuation issues, with employees potentially recovering only 42% of their investments due to significant devaluation [5] - Tencent launched an algorithm competition with substantial rewards to attract global talent, supporting its recruitment efforts and enhancing its machine learning capabilities [5] - Xiaomi's automotive factory achieved a production capacity of 20,000 to 30,000 vehicles per month, showcasing high levels of automation [6] - Gree Titanium New Energy announced a court-ordered freeze on its 100% stake in Zhuhai Guangtong Automobile, stemming from past management issues, but stated that operations remain unaffected [6] International Developments - The U.S. Department of Justice is reviewing Alphabet's proposed $32 billion acquisition of cybersecurity startup Wiz for potential antitrust concerns [8] - Santos received a non-binding acquisition offer from a consortium led by Abu Dhabi National Oil Company, valuing the company at $18.7 billion [8] - MicroStrategy announced the purchase of 10,100 bitcoins for approximately $1.05 billion, bringing its total holdings to 592,100 bitcoins [9]